Sugi Predict

Sugi Predict / Targets / RYR2

RYR2

Ryanodine receptor 2 · Q92736 · RYR2 on Sugi Atlas →

3,081 patent compounds predicted against RYR2, 1,582 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL806682 SCHEMBL806682 1.00 20/20
SCHEMBL806687 SCHEMBL806687 1.00 20/20
SCHEMBL807004 SCHEMBL807004 1.00 20/20
SCHEMBL807005 SCHEMBL807005 1.00 20/20
SCHEMBL807008 SCHEMBL807008 1.00 20/20
SCHEMBL807020 SCHEMBL807020 1.00 20/20
SCHEMBL807116 SCHEMBL807116 1.00 20/20
SCHEMBL807118 SCHEMBL807118 1.00 20/20
Aladorian Aladorian (SCHEMBL3423110) 1.00 20/20
SCHEMBL3427146 SCHEMBL3427146 1.00 20/20
SCHEMBL4112259 SCHEMBL4112259 1.00 20/20
SCHEMBL6866330 SCHEMBL6866330 1.00 20/20
SCHEMBL6866480 SCHEMBL6866480 1.00 20/20
SCHEMBL6866625 SCHEMBL6866625 1.00 20/20
SCHEMBL6866692 SCHEMBL6866692 1.00 20/20
SCHEMBL6866699 SCHEMBL6866699 1.00 20/20
SCHEMBL6866939 SCHEMBL6866939 1.00 20/20
SCHEMBL6866980 SCHEMBL6866980 1.00 20/20
SCHEMBL6866991 SCHEMBL6866991 1.00 20/20
SCHEMBL6867130 SCHEMBL6867130 1.00 20/20

Clinical trials — most relevant to RYR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract PHASE4UNKNOWN
The Re-Prosper HF Study PHASE2/PHASE3COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias. PHASE2/PHASE3COMPLETED
Levosimendan in Acute Decompensated Heart Failure PHASE2/PHASE3NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation PHASE2UNKNOWN
Antioxidant Therapy in RYR1-Related Congenital Myopathy PHASE1/PHASE2COMPLETED
S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) PHASE1COMPLETED
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a EARLY_PHASE1COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure nanUNKNOWN
International CRDS Registry nanRECRUITING
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy nanRECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
Calcium Handling and Epicardial Ablation nanCOMPLETED
A Natural History Study of RYR1-Related Disorders nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Carnosine Supplementation on Quantity/Quality of Oral Salivae. nanUNKNOWN
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage nanCOMPLETED
A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss nanCOMPLETED
Sevoflurane Effect on Left Atrial Performance: A Transoesophageal Echocardiographic Study nanCOMPLETED
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
Evaluate the Effort Test as a Therapeutic Monitoring Tool in Acute Rhabdomyolyses nanCOMPLETED
Families' Experiences of Paediatric ICC Diagnosis nanUNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a RYR2 binder may also engage these)

ProteinNameSimilarity
P30957 — 1.000 P30957 →
B0LPN4 — 1.000 B0LPN4 →
E9Q401 — 1.000 E9Q401 →
Q9TS33 — 1.000 Q9TS33 →
A2AGL3 — 1.000 A2AGL3 →
Q15413 — 1.000 Q15413 →
P11716 — 0.999 P11716 →
RYR1 Ryanodine receptor 1 0.997 landscape →
E9PZQ0 — 0.996 E9PZQ0 →
F1LMY4 — 0.994 F1LMY4 →
P16960 — 0.994 P16960 →
P29994 — 0.987 P29994 →
Q24498 — 0.985 Q24498 →
Q9TU34 — 0.984 Q9TU34 →
ITPR1 Inositol 1,4,5-trisphosphate-gated calcium channel ITPR1 0.983 landscape →
P11881 — 0.982 P11881 →
ITPR2 Inositol 1,4,5-trisphosphate-gated calcium ch 0.978 landscape →
Q28C34 — 0.977 Q28C34 →
Q8TAP6 — 0.977 Q8TAP6 →
P48553 — 0.977 P48553 →
Q0VEJ0 — 0.976 Q0VEJ0 →
Q5RCP7 — 0.975 Q5RCP7 →
Q8WN96 — 0.975 Q8WN96 →
ITPR3 Inositol 1,4,5-trisphosphate-gated calcium channel ITPR3 0.974 landscape →
Q8QFR2 — 0.974 Q8QFR2 →
Q6NYU2 — 0.974 Q6NYU2 →
P29995 — 0.973 P29995 →
Q9Z329 — 0.973 Q9Z329 →
Q6DDX8 — 0.973 Q6DDX8 →
A7MBL8 — 0.973 A7MBL8 →